The main objective of the present study was to completely characterize the metabolites of the triterpenoid saikosaponin a (SSa) in rats. To this aim, we compared the metabolites in plasma, bile, urine, and feces samples following oral and i.v. routes of administration using liquid chromatography-diode array detector coupled with hybrid ion trap-time-of-flight mass spectrometry. As a result, besides 2 known metabolites, prosaikogenin f and saikogenin f, 15 new metabolites were detected in all. It was found that SSa is metabolized mainly in phase I manner, i.e., hydration and monooxidation on the aglycone moiety and hydrolysis of the b-glucosidic bond in the liver, and sequential hydrolysis of b-glucosidic and b-fucosidic bonds followed by dehydrogenation, hydroxylation, carboxylation, and combinations of these steps on the aglycone moiety in the intestinal tract. Both the renal and biliary routes were observed for the excretion of SSa and its metabolites. Further, a clear metabolic profile in rats was proposed in detail according to the results from the in vivo animal experiment after different routes of administration. Our results update the preclinical metabolism and disposition data on SSa, which is not only helpful for the future human metabolic study of this compound but also provides basic information for better understanding of the efficacy and safety of prescriptions containing saikosaponins.
Introduction
Saikosaponins, the major bioactive ingredients of the genus Bupleurum with a long history of medicinal use, exert significant pharmacological activities, including antitumor (targeting various cancer cells) (Motoo and Sawabu, 1994; Ahn et al., 1998; Hsu et al., 2000; Tsai et al., 2002; Wen-Sheng, 2003; Hsu et al., 2004; Kim and Hong, 2011) , chemosensitizing (Wang et al., 2010a) , anti-inflammatory (Yokoyama et al., 1981; Nose et al., 1989a; Bermejo Benito et al., 1998) , immunomodulatory (Kumazawa et al., 1989; Leung et al., 2005; Sun et al., 2009) , hepatoprotective (Abe et al., 1980; Fan et al., 2007; Wu et al., 2008) , antinephritic Chen et al., 2008; Hattori et al., 2008) , antibacterial and antiviral (Kumazawa et al., 1990; Chiang et al., 2003; Cheng et al., 2006) , estrogenic (Wang et al., 2010b) , and promoting amylase secretion in rat pancreatic acini (Yu et al., 2002) . On the other hand, saikosaponins have also been reported to be responsible for toxicity induced by their hemolytic action (Abe et al., 1978a, b; Nose et al., 1989b) . Moreover, the poor selectivity resulting from the broad spectrum of pharmacological activity of saikosaponins puts at risk the clinical applications of prescriptions containing them, especially in combination with other drugs, with drug-drug interactions taken into consideration. In general, therapeutic application of saponins is very limited because of either the poor absorbance from the intestine when taken orally or the toxicity induced by marked hemolysis when administered by injection, especially i.v. (Segal et al., 1978) . Better understanding of the efficacy and safety of saikosaponins requires the elucidation of their biologic fates in the body.
Although the pharmacokinetics of saikosaponin a, b1, b2, c, and d in rats after i.v. or oral administration has been reported (Shimizu et al., 1984; Fujiwara and Ogihara, 1986; Kida et al., 1998; Tang et al., 2007; Xu et al., 2012) , there was limited knowledge about the in vivo metabolism of these compounds. Study of the metabolism of saikosaponins has mainly been focused on the artificial isomers in gastric conditions and deglycosylation metabolites by intestinal bacteria (Shimizu et al., 1985a) . Japanese researchers reported that saikosaponins are unstable in the gastric juice and prone to convert into their isomeric derivatives with the allyl oxide linkage in the 13,28 position of aglycone breaking into a heteroannular or homoannular diene. Further, these saikosaponins are hydrolyzed into their corresponding prosaikogenins and saikogenins by the hydrolyzing activities of intestinal bacteria, such as Eubacterium sp. A-44 (Kida et al., 1997) , which were also essential for the appearance of prosaikogenin a and saikogenin a in rat plasma after oral administration of saikosaponin b1 (Kida et al., 1998) . Although the total recovery of excreted saikosaponin a (SSa), prosaikogenin f (PSGf), and saikogenin f (SGf) in the feces of conventional rats was .50% of the starting dose in a period over 0 to 24 hours after the oral administration of SSa (Shimizu et al., 1985a) , the disposition of ,50% remained unexplained. The whole metabolic profile of SSa cannot be reflected by only deglycosylation metabolites such as PSGf and SGf, and so can that of the other saikosaponins. Thus we chose SSa as a representative of the saikosaponins to clarify its metabolic fate in rats using the liquid chromatography-diode array detector coupled with hybrid ion trap-time-of-flight mass spectrometry (LC-DAD-IT-TOF-MS) technique based on the work of pioneering researchers (Shimizu et al., 1984 (Shimizu et al., , 1985a Fujiwara and Ogihara, 1986; Kida et al., 1997 Kida et al., , 1998 .
Materials and Methods

Chemicals and Reagents
SSa reference standard (purity, .98%) was purchased from the National Institutes for Food and Drug Control (Beijing, China). Analytical-grade ethyl carbamate was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). High-performance LC-grade acetonitrile and methanol were purchased from Merck KGaA (Darmstadt, Germany). Analytical-grade Tween 80 was purchased from Tianjin Guangfu Fine Chemical Research Institute (Tianjin, China). Analytical-grade ethyl acetate was purchased from Nanjing Chemical Reagent Co., Ltd. (Nanjing, China). Twice-distilled water prepared in-laboratory was used throughout the study.
Dosing Procedure
Male Sprague-Dawley rats weighing 220 6 20 g were purchased from the Qinglongshan Experimental Animal Center (Nanjing, China). The animals were housed under standard conditions with food and water provided ad libitum. Animal studies were conducted under the approval of the Animal Ethics Committee of the China Pharmaceutical University.
After acclimating in stainless steel rat metabolism cages individually for 1 week, the animals were fasted for 12 hours with free access to water before the experiment. SSa dissolved in 5% Tween 80 was administrated either i.v. via the tail vein at a dose of 15 mg/kg or through intragastric gavage at a dose of 50 mg/kg. The vehicle with equal volumes was administrated by either i.v. injection or intragastric gavage to the remaining half of the animals as the control.
Sample Collection
Plasma Collection. Twelve rats were divided into four groups with three animals per group. Blood samples (about 0.5 ml) were collected in 1.5 ml sodium heparinized tubes 0. 083, 0.167, 0.333, 0.5, 1, 1.5, 3, 4.5, 6, 7.5, 9, 10 .5, and 12 hours after i.v. or oral administration of the SSa or vehicle. Plasma samples of each animal were separated by centrifugation at 3000g for 10 minutes at 4°C in an Eppendorf centrifuge 5430 R (Eppendorf, Hamburg, Germany) and pooled over 0.083 to12 hours.
Bile Collection. Twelve rats divided into four groups with three animals per group were implanted with a PE-10 cannula (Smith Medical, Ashford, UK) into the bile duct under anesthesia by ethyl carbamate. Bile samples of each animal were collected on ice and pooled over 0 to 24 hours after i.v. or oral administration of the SSa or vehicle.
Urine and Feces Collection. The urine and feces were collected separately on ice over 0 to 24 hours from another 12 rats after i.v. or oral administration of the SSa or vehicle.
All of the collected plasma, bile, urine, and feces samples were stored at 220°C before analysis.
Sample Preparation
Plasma (2 ml) was loaded on the C18 cartridge (250 mg), washed with 5 ml water, and eluted with 3 ml acetonitrile. After the evaporation of the combined acetonitrile under a stream of nitrogen gas in water bath at 35°C, the residue was dissolved in 500 ml acetonitrile-water solution (50:50 [v/v] ) for LC-DAD-IT-TOF-MS analysis. The bile and urine samples were treated by the same procedure as the plasma samples.
The feces specimens (0.5 g) were homogenized in 5 ml ice-cold acetonitrilewater solution [50:50 (v/v) ] by a homogenizer (Shanghai Jinda Biochemical Equipment Co. Ltd., Shanghai, China). The homogenate was centrifuged at 2130g for 10 minutes to separate the supernatant, which was extracted with three times its volume of ethyl acetate. After centrifugation at 2130g for 10 minutes, the ethyl acetate layer was separated and vaporized under a stream of nitrogen gas in water bath at 35°C. The residue was dissolved in 500 ml acetonitrile-water solution (50:50 [v/v] ) for LC-DAD-IT-TOF-MS analysis.
LC-DAD-IT-TOF-MS Analysis
LC experiments were conducted on a Shimadzu (Kyoto, Japan) high-performance LC system consisting of an LC-30AD binary pump, a DGU-20As degasser, a SIL-30AC autosampler, and a CTO-20AC column oven. Chromatographic separation was achieved on a Shimadzu VP-ODS column (150 mm Â 2.0 mm, 2.2 mm) (Shimadzu) at 40°C. The mobile phase (delivered at 0.4 ml/min) comprised solvent A, acetonitrile-methanol solution (80:20 [v/v] ), and solvent B, 0.06% HCOOH in water. A gradient elution was performed: 20-40% A for 0-20 minutes, 40-50% A for 20-60 minutes, 95% A for 60-70 minutes, and 20% A for 70-90 minutes. The UV absorption from 190 to 400 nm was recorded by an SPD-M20A diode array detector (Shimadzu) to determine whether the allyl oxide linkage in the 13,28 position of the aglycone moiety was broken into a heteroannular or homoannular diene (Kubota et al., 1966; Kubota and Hinoh, 1968) .
MS analyses were conducted on a Shimadzu IT-TOF-MS (Shimadzu, Kyoto, Japan) equipped with an electrospray ionization source. MS 1 analysis was carried out in positive and negative mode simultaneously, followed by MS n analyses in positive mode and MS n analyses in negative mode, respectively. Some important equipment parameters were as follows: electrospray voltage, +4.5 kV for positive mode and 23.5 kV for negative mode; nebulizer gas (N 2 ) flow, 1. After the data acquisition, MetID solution 1.2 (Shimadzu) was used to screen metabolite candidates. SSa, PSGf, and SGf were chosen as three templates in the mass defect filter method (Zhu et al., 2006; Zhang et al., 2009 ) with a mass defect window of 60.050 Da.
Results
Fragment Pattern of SSa
At first, both the positive and negative MS fragment patterns of SSa were analyzed. Besides the typical adduct ion [M+K] + at m/z 819. Fig. 1 ). The mass fragmentation pathway is proposed in Fig. 2 .
In the negative full-scan mass spectrum, two major ions, the [M+HCOO] 2 at m/z 825. ). This fragmentation was in agreement with the previous findings (Huang et al., 2008) . The positive and negative MS n analysis was applied to identify the structures of the aglycone part and glycosyl group, respectively, in this experiment. 
Screening of Metabolites
With the aid of the MetID solution 1.2 software, the metabolites were screened by comparing the full-scan mass spectra of the plasma, bile, urine, and feces of rats after administration of SSa with that of the control samples of rats after administration of vehicle. A total of 17 metabolites were detected besides the parent drug. The extracted ion chromatograms of the typical biosamples are shown in Fig. 3 . Information on the parent compound and metabolites is summarized in Tables 1 and 2 . in the MS 3 spectrum. This fragment pattern was identical to that of hydroxysaikosaponin a (HOSSa) as reported previously (Huang et al., 2008) . Further, we validated this inference by comparison of its retention time with that of HOSSa derived from SSa in aqueous condition. Thus M13 was identified as HOSSa. The conversion of SSa to HOSSa, which can occur to a limited extent in aqueous solvent, may accelerate in vivo. spectrum of the precursor ion at m/z 455.3541 to that of the parent compound indicated that M1 has the same aglycone as SSa, which was confirmed by its UV end absorption. The same negative MS/MS spectrum of the precursor ion at m/z 617.4076 as that of the parent compound showed the linkage of a deoxyhexose to the aglycone. These spectral data were in agreement with those of PSGf as reported in the literature (Huang et al., 2008 2 at m/z 517.3513 (C 31 H 49 O 6 ) in the negative full-scan mass spectrum. The similar positive MS 2 spectrum of the precursor ion at m/z 455.3527 to that of the parent compound suggested that M2 has the same aglycone as the parent compound, which was also confirmed by the UV end absorption. So M2 was identified as SGf as reported previously (Shimizu et al., 1985b O, 100% relative signal intensity) were 2 Da less than ion L1 and L1-H 2 O, respectively. These results indicated that the dehydrogenation of both M3 and M4 took place on the AB ring part structure. The fragment ion of M3 at m/z 175.1479 (C 13 H 19 , L2-H 2 O-CO) resulting from neutral loss of CO from 203.1428 suggested that M3 has a ketone carbonyl group on the ring that should locate at C3. So M3 was inferred as 3-keto-SGf. As to M4, the fragment ion at m/z 425.3399, 419.3295, 407.3296, 401.3224, 389.3199, 299.2361, 285.2213, 283.2049, 267.2123, 265.1946, 253.1961, 251.1805, 241.1945, 239.1811, 233.1897, 231.1755, 223.1689, 215.1789, 213.1648, 205.1584, 201.1634 Fig. 4, A + at m/z 453.3369 were consistent with R7+O-H 2 O and R7+O-2H 2 O, respectively, indicating that hydroxylation took place on the CDE ring part structure of M6 and the added hydroxyl group may be at C19, C21, C22, C27, C29, or C30. The key MS fragmentation of M6 is shown in Fig. 4D . O-HCOOH) showed one carboxyl function and two hydroxyl groups on the CDE ring part structure and eliminated the possibility of carboxylation at C29 or C30. The end absorption in UV spectrum ruled out the possibility of carboxylation at C28, which otherwise needed the 13,28-oxide bridge to break into a heteroannular or homoannular diene. Taken together, M7 was tentatively characterized as SGf-27-oic acid, and its key MS fragmentation is presented in Fig. 4E .
M14 and M15 (Monooxidation
M7(Carboxylation and Hydrolysis of b-Fucosidic Bond
M8 and M10 (Hydroxylation, Carboxylation, and Hydrolysis of b-Fucosidic Bond). As an isomer of M7, the MF of M8 was also determined as C 30 H 46 O 6 , with two oxygens more and two hydrogens fewer than M2, based on the positive and negative full-scan mass spectra. The CDE ring part structure of this metabolite remained unchanged according to its fragment ions at m/z 233. The accurate mass data with error (ppm) for fragment ions of all metabolites are listed in Supplemental Table 1 .
Discussion
The main objective of the present study was to completely characterize the metabolites of the triterpenoid SSa in rats. To this aim, we compared the metabolites in plasma, bile, urine, and feces samples following oral and i.v. routes of administration. Our results showed that SSa is metabolized diversely. The metabolic profile is proposed in Fig. 5 . The observed routes of SSa metabolism are some types of oxidation such as dehydrogenation, hydroxylation, carboxylation, and combinations of these steps on the aglycone moiety, in addition to the previously reported hydrolysis of glycosidic bonds (Shimizu et al., 1985a; Kida et al., 1998) .
The detected metabolites in biosamples differ via different routes of administration, as summarized in Table 1 . So a relative comprehensive information of in vivo experience of SSa was deduced from the complementary results after different routes of administration, as shown in Fig. 6 . After intravenous dosing, SSa was oxidized into M14 and M15 in the liver, as indicated by their detection in the bile. Interestingly, the b-glucosidic bond of SSa, M14, and M15 was hydrolyzed to produce M1, M16, and M17, respectively, as detected in the bile, suggesting that the hydrolyzing activity for the b-glucosidic bond exists not only in the intestinal bacteria but also in the liver. This inference is supported by other reports that various soluble and membrane-bound b-glucosidase with broad specificity catalyzing such reactions had been detected in most mammalian tissues (Robinson, 1956; Abrahams and Robinson, 1969; Glew et al., 1976; Daniels et al., 1981) . SSa and M13-M17 excreted through the bile duct were metabolized further in the intestine, according to their disappearance in the feces. In the intestine, SSa was metabolized through hydrolysis mediated by the intestinal flora following oxidation catalyzed by the metabolizing enzymes in the intestinal mucosal cells (Kaminsky and Zhang, 2003; Zhang et al., 2007) . Both the renal and biliary routes were observed for the excretion of SSa and its metabolites. In the case of oral administration, M1-M4 and M7-M12 produced in the intestine were partly absorbed into the systemic circulation, as indicated by their excretion in the urine. This may be due to their improved permeability through the intestinal membrane after hydrolysis of glycosidic bonds because the permeability decreased in the order of saikogenin a, prosaikogenin a, and saikosaponin b1, as reported previously (Kida et al., 1998) . Additionally, our results showed that no saikosaponin b1 or g, prosaikogenin a or h, or saikogenin a or h was detected in all the biosamples after oral administration of SSa, suggesting the negligible effect of gastric juice on the allyl oxide linkage in the 13,28 position, which was consistent with the findings of Shimizu et al. (1985a) . Furthermore, various bioactivities of saikosaponins might be linked closely to their interaction with biomembranes of cells which appeared to intimately parallel their degree of hemolytic activity (Ahn and Sok, 2006) . Previous structure-activity relationship research showed that for these activities the ether linkage between C13 and C28, the 23-CH 2 OH, the configuration of the hydroxyl group at C16, and the proper polar balance between the sugar moiety (polar position) and the aglycone moiety (nonpolar position) are important (Abe et al., 1980; Yokoyama et al., 1981; Nose et al., 1989a,b; Kumazawa et al., 1990; Ahn et al., 1998; Tsai et al., 2002) . In this experiment, the ether linkage between C13 and C28 of all identified metabolites except M13 didn't cleave according to their UV spectra. The configuration of the hydroxyl group at C16 of SSa was b type and so should be that of its metabolites. The polar balance of metabolites had been broken after the hydrolysis of glycosidic bonds but was compensated to some degree by the addition of hydroxyl and carboxyl groups on the aglycone moiety. It is believed that the addition of functional groups such as -OH, -COOH, -SH, -O-, or -NH 2 by the phase I enzymes can dramatically alter the biologic properties of the drug (Brunton et al., 2008) . As to saikosaponins, the -OH was proven important for their interaction with the cell surface based on the fact that whereas the transformation of the 23-methyl group (saikosaponin e) to CH 2 OH (SSa) resulted in twofold enhancement in the anti-cell adhesive activity on the whole, the acetylation of this carbinol group to form 23-O-acetylsaikosaponin-a led to a substantial loss of action (Ahn et al., 1998) . Thus, the introduction of the hydroxyl and carboxyl group on the aglycone moiety may lead to the marked change of activities, which is of significance for the development of saikosaponins in the pharmaceutical industry. In addition, we also detected two dehydrogenating metabolites, M3 and M4, in both the feces and urine of rats after oral dosing of SSa. The addition of unsaturated group on M3 and M4 may make them function as electrophiles that can react with nucleophilic cellular macromolecules such as DNA, RNA, and protein. Further assessment of the exposure and activities of these metabolites still needs to be conducted.
To summarize, the metabolic profile of SSa in rats has been characterized in detail by comparing the results following different routes of administration using LC-DAD-IT-TOF-MS. The observed routes of SSa metabolism involve hydration and monooxidation on the aglycone moiety and hydrolysis of the b-glucosidic bond in the liver and various types of oxidation including dehydrogenation, hydroxylation, and carboxylation on the aglycone moiety following sequential hydrolysis of both b-glucosidic and b-fucosidic bonds in the intestinal tract. SSa and its metabolites can be excreted through both the renal and biliary routes. These results may provide valuable information for assessing the efficacy and safety of clinical applications of prescriptions containing saikosaponins. Moreover, the discussion of oxidation on the aglycone moiety gives us some clues for structural modification of these promising compounds.
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